A balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients
Molly S. Cook, Ellen King, Katie R Flaherty, Khadiza Siddika, Sophie Papa, Reuben Benjamin, Anna Schurich
Ex vivo profiling of patient CD19 CAR-T cells shows CD28 products skew glycolytic and effector-like while 4-1BB products favor OXPHOS; complete responders show balanced metabolism.
Cell Reports · Jul 1, 2025Peer-reviewedImmunology✦ In-depth digest